APTX - Aptinyx Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Aptinyx Inc.

909 Davis Street
Suite 600
Evanston, IL 60201
United States

Full Time Employees63

Key Executives

NameTitlePayExercisedYear Born
Dr. Norbert G. RiedelPres, CEO & Director665.18kN/A1958
Mr. Ashish KhannaCFO & Chief Bus. Officer477.81kN/A1976
Mr. Andrew Kidd B.M. B.Ch.Chief Operating Officer466.64kN/A1976
Mr. Juan EstupinanVP of Fin. & Accounting and ControllerN/AN/AN/A
Ms. Patricia M. AdamsVP of HR & Admin.N/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc to develop a compound for the treatment of major depressive disorder. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.

Corporate Governance

Aptinyx Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.